Black Rock Inc. T Scan Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,462,352 shares of TCRX stock, worth $23.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,462,352

Previous 1,699,213 162.61%

Holding current value

$23.7 Million

Previous $13.5 Million 93.49%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.85 - $9.51 $16.2 Million - $26.3 Million	2,763,139 Added 162.61%	4,462,352 $26.1 Million
Q1 2024 May 10, 2024	BUY	$4.89 - $8.3 $134,406 - $228,133	27,486 Added 1.64%	1,699,213 $13.5 Million
Q4 2023 Feb 13, 2024	SELL	$2.66 - $6.76 $23,200 - $58,960	-8,722 Reduced 0.52%	1,671,727 $9.75 Million
Q3 2023 Nov 13, 2023	BUY	$2.04 - $2.94 $850,671 - $1.23 Million	416,996 Added 33.0%	1,680,449 $4.3 Million
Q2 2023 Aug 11, 2023	SELL	$1.64 - $4.85 $412,619 - $1.22 Million	-251,597 Reduced 16.61%	1,263,453 $3.16 Million
Q1 2023 May 12, 2023	BUY	$1.66 - $3.32 $1,832 - $3,665	1,104 Added 0.07%	1,515,050 $3.18 Million
Q4 2022 Feb 13, 2023	BUY	$1.49 - $3.33 $195 - $436	131 Added 0.01%	1,513,946 $2.35 Million
Q3 2022 Nov 14, 2022	SELL	$2.62 - $4.39 $3,010 - $5,044	-1,149 Reduced 0.08%	1,513,815 $4.62 Million
Q2 2022 Aug 12, 2022	SELL	$1.65 - $3.58 $6,969 - $15,121	-4,224 Reduced 0.28%	1,514,964 $4.77 Million
Q1 2022 May 12, 2022	BUY	$2.8 - $5.4 $57,819 - $111,510	20,650 Added 1.38%	1,519,188 $4.25 Million
Q4 2021 Feb 10, 2022	SELL	$4.5 - $9.05 $9,175 - $18,452	-2,039 Reduced 0.14%	1,498,538 $6.74 Million
Q3 2021 Nov 09, 2021	BUY	$6.17 - $13.48 $9.26 Million - $20.2 Million	1,500,577 New	1,500,577 $12.5 Million

Others Institutions Holding TCRX

# of Institutions

Shares Held

36M

Call Options Held

Put Options Held

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $100M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account